Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics (NASDAQ:DRMA) reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its new Tome brand.

Rhea-AI Summary

Dermata Therapeutics (NASDAQ:DRMA) reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its new Tome brand. The company expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with manufacturing and packaging completed and a social media campaign underway.

As of June 30, 2026, Dermata held $4.4 million in cash and cash equivalents versus $7.5 million at year-end 2025, and expects this to fund operations into Q4 2026. Q2 2026 research and development expenses declined to $0.2 million, while selling, general and administrative expenses rose to $2.8 million driven by higher legal, marketing, commercialization, and reallocated employee costs. Total assets were $5.3 million, equity was $3.5 million, and the company reported a Q2 2026 net loss of $3.0 million, or $(0.74) per share.

Positive

• First product launch set for August 25, 2026, with manufacturing and packaging completed for Tome Foundational Treatment
• Cash runway expected to fund operations into the fourth quarter of 2026 based on current resources
• Research and development expenses down to $0.2 million in Q2 2026 from $0.6 million in Q2 2025
• ATM financing proceeds of approximately $1.9 million in the first half of 2026
• Growing share base with 4.0 million weighted average common shares outstanding in Q2 2026 versus 1.0 million in Q2 2025

Negative

• Net loss widened to $3.0 million in Q2 2026 from $1.7 million in Q2 2025
• Cash and cash equivalents decreased to $4.4 million from $7.5 million over six months
• Selling, general and administrative expenses more than doubled to $2.8 million in Q2 2026 from $1.2 million in Q2 2025
• Equity declined to $3.5 million at June 30, 2026 from $6.2 million at December 31, 2025
• Operating cash used of $4.9 million for the six months ended June 30, 2026

News Explained

The company has cash from an approximately $1.9 million ATM financing, but its effect on existing ownership is undisclosed as the first product remains pre-launch.

The company reported that manufacturing and packaging for Tome Foundational Treatment were finished and that its first direct-to-consumer launch is expected on August 25, 2026.

Thus, the product is prepared but not yet reported as launched, while the release reports approximately $1.9 million in ATM financing proceeds during the six months ended June 30, 2026.

The release does not provide the ATM issuance's security count, price, dilution, conversion terms, or use of proceeds, so the financing's effect on existing ownership cannot be established from this disclosure.

The six-month cash bridge reports $4.9 million used in operations and $0.1 million used in investing, offset by the $1.9 million ATM proceeds; cash and equivalents were $4.4 million at June 30, 2026.

The next stated checkpoint is August 25, 2026, when the expected launch can be checked against the company's prepared-but-not-launched status; the second OTC product remains described only as expected sometime after the first.

Argus Aug 12 session 50 alerts

+26.85% close to close 9400.6x rel. volume Open Argus

Details

News Market Reaction – DRMA

+8.2% Peak Tracked

-18.2% Trough Tracked

$6.59M Market Cap

On Aug 12, the first trading day after this news, DRMA closed 26.85% above the previous close. Argus tracked a peak move of +8.2% during that session. Argus tracked a trough of -18.2% from its starting point during tracking. Our momentum scanner recorded 50 alerts for this stock that day. Relative volume reached 9400.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 12 session.

Key Figures

Product launch date: August 25, 2026 Cash and equivalents: $4.4M Cash decrease: $3.1M +5 more

Product launch date

August 25, 2026

Tome Foundational Treatment

Cash and equivalents

$4.4M

As of June 30, 2026, versus $7.5M at December 31, 2025

Cash decrease

$3.1M

Six months ended June 30, 2026

Cash used in operations

$4.9M

Six months ended June 30, 2026

Cash runway

Fourth quarter of 2026

Expected funding period from current cash resources

Net loss

$2.967M

Quarter ended June 30, 2026

R&D expenses

$0.2M

Quarter ended June 30, 2026, versus $0.6M in Q2 2025

SG&A expenses

$2.8M

Quarter ended June 30, 2026, versus $1.2M in Q2 2025

Previous Earnings Reports

5 past events · Latest: May 13

Same Type 5 events

1. May 13

   1Q26 earnings report

   24h Move

   +3.4%

   DTC pivot, ATM proceeds, cash position, and planned Tome launch

2. Mar 26

   FY25 earnings report

   24h Move

   -13.9%

   Strategic pivot, financing history, cash runway, and discontinued prescription program

3. Nov 14

   3Q25 earnings report

   24h Move

   -7.5%

   Positive Phase 3 results, OTC strategy, and cash runway

4. Aug 13

   2Q25 earnings report

   24h Move

   -9.8%

   Positive Phase 3 results, financing, cash balance, and expense changes

5. May 14

   1Q25 earnings report

   24h Move

   -0.1%

   Positive Phase 3 results, collaboration agreement, financing, and cash runway

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

direct-to-consumer, over-the-counter (otc), atm financing, stock-based compensation

4 terms

direct-to-consumer financial

"become a commercial-stage, direct-to-consumer skincare company"

A direct-to-consumer (DTC) model is when a company sells its products or services straight to customers, skipping middlemen like retailers or wholesalers. For investors, DTC matters because it can mean higher profit margins, closer customer relationships and faster feedback—like a baker who sells directly from the shop instead of through a grocery chain—while also exposing the business to costs for marketing, customer support and logistics that affect growth and profitability.

over-the-counter (otc) regulatory

"a once weekly, over-the-counter (OTC) topical treatment for acne"

Over-the-counter (OTC) describes stocks and other securities traded directly between buyers and sellers outside formal exchanges, using brokers, dealers, or electronic networks. For investors it matters because OTC trading often means lower transparency, fewer rules and thinner trading volume—like buying at a small flea market instead of a big supermarket—so prices can swing more and the risk of not being able to sell quickly is higher.

atm financing financial

"offset by approximately $1.9 million of ATM financing proceeds"

At-the-market (ATM) financing is a way for a public company to raise money by selling newly issued shares directly into the open market at the prevailing market price, often in small amounts over time through a broker. It matters to investors because it can dilute existing ownership and affect share price, but it gives the company flexibility to raise capital as needed without a large, single stock sale—similar to restocking and selling items gradually at current store prices.

stock-based compensation financial

"Includes the following stock-based compensation expense"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.

"Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO. "This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we've identified the untapped 'white space' to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues in the near future while continuing to build long-term value for our shareholders," continued Mr. Proehl. "Looking ahead, we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement, and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to come," concluded Mr. Proehl.

Corporate Highlights

• Attended first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand. In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially launch the Tome brand and provided attendees with more information on the upcoming launch of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa, and wellness professionals with over 400+ brands in attendance.

• Began social media campaign for its new skincare brand, Tome. The Company recently unveiled the Tome brand's official social media presence as part of the Company's broader commercial launch strategy. These efforts are designed to increase brand awareness, engage prospective consumers, and support the successful ecommerce launch of the Company's first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026.

Anticipated Upcoming Milestones

• Launch first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application.

• Continue development of a second DTC product. The Company is also working on its second skincare product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected to launch sometime after its Foundational Treatment.

Second Quarter 2026 Financial Results

As of June 30, 2026, the Company had $4.4 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $3.1 million decrease in cash and cash equivalents for the six months ended June 30, 2026, resulted from $4.9 million of cash used in operations, and $0.1 million of cash used in investing activities, offset by approximately $1.9 million of ATM financing proceeds. The Company expects its current cash resources to be sufficient to fund operations into the fourth quarter of 2026.

Research and development expenses were $0.2 million for the quarter ended June 30, 2026, compared to $0.6 million for the quarter ended June 30, 2025. The $0.4 million decrease in research and development expenses resulted primarily from the Company's decision to prioritize the commercial launch of its first product, resulting in a decrease in research and development efforts during the three months ended June 30, 2026. As the Company continues to focus on branding, marketing, and manufacturing of its first commercial product, the Company reallocated its resources, including employee efforts, toward the pre-commercial launch and anticipates that research and development expenses will continue to decrease compared to prior periods.

Selling, general and administrative expenses were $2.8 million for the quarter ended June 30, 2026, compared to $1.2 million for the quarter ended June 30, 2025. The increase in selling, general and administrative expenses was primarily attributable to $0.7 million of increased legal fees, an increase of $0.6 million of marketing and other commercialization expenses, and an increase of $0.3 million of employee compensation attributable to a reallocation of employee efforts from research and development activities toward pre-commercial activities in anticipation of the Company's first product launch.

About Dermata Therapeutics

Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata's Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.

About Tome

Tome is Dermata's new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome will consist of a line of skincare products incorporating its Bioneedle, utilizing Spongilla lacustris, a wild harvested, freshwater sponge that has evolved over millions of years, as the primary ingredient for consumers that are compelled by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line will simplify existing skincare routines with essential ingredients that deliver results, without the recovery associated with in-office treatments. Dermata expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with additional product launches planned to follow. Start your skincare story at www.tomeskincare.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize DTC and OTC skincare products; the anticipated benefits of Dermata's strategic shift to prioritize DTC and OTC skincare products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Foundational Treatment; the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the Company's products and their ability to generate revenue for the Company; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

 

DERMATA THERAPEUTICS, INC.
Balance Sheets

In thousands USD		June 30, 2026				December 31, 2025
		(unaudited)
Assets
Cash and cash equivalents		$	4,413			$	7,522
Prepaid expenses and other current assets			594				342
Inventories			150				-
Non-current assets			164				-
Total assets			5,321				7,864
Liabilities
Accounts payable			1,120				461
Accrued liabilities			713				1,180
Total liabilities			1,833				1,641
Equity			3,488				6,223
Total liabilities and equity		$	5,321			$	7,864

DERMATA THERAPEUTICS, INC.
Statements of Operations
(unaudited)

		Quarter Ended June 30,								Six Months Ended June 30,
In thousands, except share and per share data		2026				2025				2026				2025
Operating expenses
Research and development (1)		$	213			$	618			$	596			$	1,899
Selling, general and administrative (1)			2,801				1,155				4,344				2,214
Total operating expenses			3,014				1,773				4,940				4,113
Loss from operations			(3,014	)			(1,773	)			(4,940	)			(4,113	)
Interest income			47				72				125				108
Net loss		$	(2,967	)		$	(1,701	)		$	(4,815	)		$	(4,005	)
Net loss per common share, basic and diluted		$	(0.74	)		$	(1.66	)		$	(1.22	)		$	(5.18	)
Weighted average common shares outstanding, basic and diluted			4,022,143				1,026,506				3,940,983				772,397
(1) Includes the following stock-based compensation expense
Research and development		$	4			$	8			$	18			$	16
Selling, general and administrative		$	38			$	31			$	67			$	61

Investor Contact:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com

SOURCE: Dermata Therapeutics

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dermata Therapeutics (NASDAQ:DRMA) report in its Q2 2026 financial results?

Dermata reported a Q2 2026 net loss of $3.0 million, or $(0.74) per share. According to Dermata, total operating expenses were $3.0 million, driven mainly by $2.8 million in selling, general and administrative costs and $0.2 million in research and development spending.

When will Dermata Therapeutics launch its Tome Foundational Treatment product?

Dermata expects to launch Tome Foundational Treatment on August 25, 2026. According to Dermata, manufacturing and packaging are complete, and the product will be sold via a direct-to-consumer ecommerce strategy supported by trade show exposure and a dedicated social media campaign.

How much cash does Dermata Therapeutics (DRMA) have after Q2 2026 and what is its runway?

Dermata reported $4.4 million in cash and cash equivalents as of June 30, 2026. According to Dermata, current cash resources, including ATM proceeds, are expected to fund operations into the fourth quarter of 2026, assuming its present operating plan and spending levels.

How did Dermata Therapeutics’ expenses change in Q2 2026 compared to Q2 2025?

Research and development expenses fell to $0.2 million, while selling, general and administrative costs rose to $2.8 million. According to Dermata, lower research spending reflects resource reallocation toward branding, marketing, and pre-commercial activities ahead of its first product launch.

What strategic pivot is Dermata Therapeutics making with its Tome skincare line?

Dermata is pivoting from pharmaceutical development to direct-to-consumer skincare via its Tome brand. According to Dermata, the company aims to build a scalable DTC platform, using data-driven marketing to launch Tome Foundational Treatment and subsequent Bioneedle-based skincare products.

What are the key balance sheet figures for Dermata Therapeutics at June 30, 2026?

Dermata reported total assets of $5.3 million, liabilities of $1.8 million, and equity of $3.5 million. According to Dermata, cash was $4.4 million, with inventories of $0.2 million and prepaid and other current assets of $0.6 million supporting the upcoming product launch.